Teva Pharma and Alvotech launch Stelara biosimilar in US
21/02/2025 11:09
Feb 21 (Reuters) - Teva Pharmaceuticals TEVA.TA and Alvotech ALVO.O said on Friday they have launched a biosimilar to Johnson & Johnson's JNJ.N autoimmune disease drug Stelara in the United States. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Alvotech SA
See all newsBrief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Brief: Alvotech and Teva Secure U.S. Settlement Date For AVT06
India's Dr Reddy's rises after EU marketing authorisation for osteoporosis biosimilar
Brief: UK High Court Rules In Favor Of Alvotech Paving Way For AVT06, Biosimilar To Eylea
U.S. STOCKS ON THE MOVE-Cummins, EPAM Systems, Qualcomm